Spectral AI reported Q2 2026 financial results with a net loss of $(4.2) million, or $(0.13) per share, compared to a $(8.0) million loss in the prior year period. R&D revenue declined to $3.5 million from $5.1 million due to reduced BARDA contract reimbursements following FDA clearance of the DeepView System for burn indication. The company drew $6.5 million under its credit facility with Avenue Capital Group, ending Q2 2026 with $14.0 million in cash. Management reiterated full-year revenue guidance of approximately $18.5 million and aims to generate first commercial sales by year-end 2026. Spectral AI operates in the medical diagnostics industry, developing artificial intelligence technology for wound care assessment.